InvestorsHub Logo
Followers 86
Posts 38352
Boards Moderated 0
Alias Born 05/09/2017

Re: None

Wednesday, 06/28/2017 12:16:54 AM

Wednesday, June 28, 2017 12:16:54 AM

Post# of 107737
Is this product helping consumers determine whether or not they want to smoke a certain strain of cannabis before they smoke it? Is this product helping consumers communicate with MYDX verification that a certain strain could have a certain effect for someone interested in similar results as research before they invest in a cannabis purchase? The answer to these quintessential questions is undoubtedly YES and this is what I love about MYDX and what it is doing for consumers through CannaDX. Big deal if someone tells me a certain strain works for them, I want to be able to test it for myself. MYDX will allow me to test a strain I've had that made me feel sick and caused vomiting and dizziness. I love that I will be able to test what strain that was so I know through the "trust and verify" process that I will never put that strain in my body ever again! This is just cannabis, MYDX is so much more but what it accomplishes is exactly what it set out to do from day one and that is allow consumers the opportunity to "trust and verify" something before they expose it to their bodies, and as far as AeroDX, I believe, there will be sensors you can place in a room that will monitor the air so that before someone enters it, they will be able to know if the air is toxic. For sure, if a room's air is toxic after you enter it, AeroDX will let you know. If someone hates this product or company, it can't be for these reasons, so that's what I will never understand about people who say they hate this company and products. I'm not going to ask questions leading to the conclusion that people involved in companies such as big pharma just don't want MYDX to succeed because it is a threat to their market share in their industry.

MYDX is HIPPA compliant, important? You be the judge after considering the following (reference links to follow):

"We are finally getting to the heart of what ailments people are tracking and more importantly, what unique chemicals profiles are helping them find relief," stated Yazbeck. "By mining this HIPPA Compliant Data, we are now identifying the specific green Active Pharmaceutical Ingredients (gAPI) that can be derived from cannabis, as well as the dosage of each ingredient that should go into a formulation so it can be tailored for a specific therapy."

http://ir.cdxlife.com/press-releases/detail/59/a-problematic-truth-and-a-solution-in-the-making

MYDX Why gAPI is so valuable (link reference to follow):

"...we are now identifying the specific green Active Pharmaceutical Ingredients (gAPI) that can be derived from cannabis, as well as the dosage of each ingredient that should go into a formulation so it can be tailored for a specific therapy. This information not only supports an active engaged community, but also provides the basis for our Company to partner, sell and supply smart devices and formulations to the various communities we service so they can benefit from tailored cannabis therapies that meet their specific needs."

http://ir.cdxlife.com/press-releases/detail/59/a-problematic-truth-and-a-solution-in-the-making

Is HIPPA compliance important (reference link to follow)?

"When dealing with patient ePHI, having a HIPAA compliant provider offers practitioners multiple benefits and peace of mind against impending audits."

http://blog.corespace.com/the-benefits-of-a-hipaa-compliant-provider

MYDX setting itself apart in medicinal cannabis market (reference link to follow):

"Since the inception of MyDx's handheld testing device, MyDx has been accumulating data tying the net physiological effects of cannabis to its chemical profile and is the only company in the industry that actively collects this sort of data with such specificity. And this has created a whole new business segment that is tied to the pharmaceutical industry."

http://ir.cdxlife.com/press-releases/detail/59/a-problematic-truth-and-a-solution-in-the-making

https://www.google.com/amp/s/amp.theguardian.com/us-news/2017/apr/03/big-pharma-marijuana-competition-insys-arizona

Why would Big Pharma want to stop something they don't care to get into?
Big Pharma let MYDX take the risk? Is it because Big Pharma knows it will be years before cannabis becomes legal at federal level even though it is becoming legal by the states? Is it because Big Pharma knows they can just buy into MYDX's first to market smart medicinal cannabis vape pens due to market availability by end of this year? Big Pharma will have to go through MYDX? What effect will this have on current shareholders?
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.